Kyverna TherapeuticsKYTX
KYTX
About: Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Employees: 119
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
22% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 23
6% more funds holding
Funds holding: 88 [Q2] → 93 (+5) [Q3]
5% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]
9.22% less ownership
Funds ownership: 74.36% [Q2] → 65.13% (-9.22%) [Q3]
43% less capital invested
Capital invested by funds: $241M [Q2] → $138M (-$102M) [Q3]
90% less call options, than puts
Call options by funds: $7K | Put options by funds: $67K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
50%
upside
Avg. target
$14.33
258%
upside
High target
$24
500%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
HC Wainwright & Co. Mitchell Kapoor 25% 1-year accuracy 41 / 164 met price target | 50%upside $6 | Neutral Maintained | 20 Nov 2024 |
Wells Fargo Derek Archila 53% 1-year accuracy 19 / 36 met price target | 500%upside $24 | Overweight Maintained | 15 Nov 2024 |
UBS Trung Huynh 40% 1-year accuracy 2 / 5 met price target | 225%upside $13 | Buy Initiated | 10 Oct 2024 |
Financial journalist opinion
Based on 151 articles about KYTX published over the past 30 days
Neutral
Accesswire
2 hours ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTX
NEW YORK, NY / ACCESSWIRE / December 21, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=117913&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
7 hours ago
The Schall Law Firm Urges Shareholder Participation In A Securities Fraud Case Against Kyverna Therapeutics Inc
LOS ANGELES, CA / ACCESSWIRE / December 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering ("IPO") conducted on February 8, 2024, are encouraged to contact the firm before February 7, 2025.
Neutral
Accesswire
13 hours ago
Class Action Announcement (KYTX): A Securities Fraud Class Action Lawsuit Was Filed Against Kyverna Therapeutics, Inc. (KYTX)
RADNOR, PA / ACCESSWIRE / December 21, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP(www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna") (NASDAQ:KYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna's February 8, 2024 initial public offering ("IPO"). The lead plaintiff deadline is February 7, 2025.
Neutral
GlobeNewsWire
21 hours ago
KYTX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) common stock pursuant and/or traceable to Kyverna's registration statement issued in connection with Kyverna's initial public offering (the “IPO”) held on February 8, 2024, have until February 7, 2025 to seek appointment as lead plaintiff of the Kyverna class action lawsuit. Captioned Rondini v. Kyverna Therapeutics, Inc., No. 24-cv-08869 (N.D. Cal.), the Kyverna class action lawsuit charges Kyverna as well as certain of Kyverna's top current and former executives and directors, and certain underwriters of Kyverna's IPO with violations of the Securities Act of 1933.
Neutral
PRNewsWire
22 hours ago
KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX
NEW ORLEANS , Dec. 20, 2024 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 7, 2025 to file lead plaintiff applications in a securities class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NasdaqGS: KYTX), if they purchased the Company's shares pursuant and/or traceable to the Company's registration statement issued in connection with its February 2024 initial public offering ("IPO").
Neutral
GlobeNewsWire
1 day ago
ROSEN, A TOP RANKED LAW FIRM, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – KYTX
NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to the Kyverna's initial public offering conducted on February 8, 2024 (the “IPO”), of the important February 7, 2025 lead plaintiff deadline.
Neutral
Accesswire
1 day ago
Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=117892&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
1 day ago
Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 202- KYTX
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=117880&wire=1 or contact Joseph E. Levi, Esq.
Neutral
PRNewsWire
1 day ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTX
NEW YORK , Dec. 20, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ: KYTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Neutral
Accesswire
1 day ago
February 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against KYTX
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=117866&wire=1 or contact Joseph E. Levi, Esq.
Charts implemented using Lightweight Charts™